Editorial Comment 1

The document discussed the findings of a study that extended observations from the Prostate Cancer Prevention Trial (PCPT) regarding the use of finasteride to reduce prostate cancer risk. This study differed from the PCPT in several ways: it had a smaller sample size, was a retrospective analysis, lacked central pathology review, used a different agent inhibiting both isoforms of 5-alpha-reductase, and involved participants with generally higher PSA values and clinical symptoms of BPH. Despite these differences, like the PCPT, participants underwent annual examinations with digital rectal exams and PSA measurements.